BioPharmSignal logoBioPharmSignal

Biotech News

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

ALX Oncology (ALXO)ALX OncologyClinical readout

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease Subgroup analyses support CD47 expression as a predictive

Related news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

INBXInhibrx2026-09-08 11:30 EST

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

TEVATeva Pharmaceutical Industries2026-09-02 11:03 EST

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

View all latest news

ALX Oncology

CD47-Directed Immuno-Oncology ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells. Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other...

Recent company news

ALXOALX Oncology2026-09-28 12:00 EST

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

ALXOALX Oncology2026-09-28 12:00 EST

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

ALXOALX Oncology2026-09-02 12:00 EST

ALX Oncology to Present at Upcoming Investor Conferences in September

ALXOALX Oncology2026-09-02 12:00 EST

ALX Oncology to Present at Upcoming Investor Conferences in September

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
1.30 USD
Market cap
239.52M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States